Novo Nordisk’s Weight Loss Drugs Like Wegovy, Ozempic May Pose Serious Stomach Risks, Study Suggests
A recent study published in JAMA has raised concerns about the potential risks associated with popular weight loss and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO), Wegovy (semaglutide), Ozempic (semaglutide), and Saxenda (liraglutide).